Beijing Health Guard Biotechnology Co., Ltd., BDA, Daxing District, Beijing, 100176, PR China.
Beijing Health Guard Biotechnology Co., Ltd., BDA, Daxing District, Beijing, 100176, PR China; National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China; School of Chemical and Engineering, University of Chinese Academy of Sciences, Beijing, 100049, China.
Papillomavirus Res. 2020 Dec;10:100209. doi: 10.1016/j.pvr.2020.100209. Epub 2020 Nov 13.
Human papillomavirus (HPV) causes not only most cervical cancers but also cancers of the vagina, vulva, penis, anus, rectum, and oropharynx. Every year, 200,000 women die of cervical cancer in the world, and China accounts for about 10%. HPV vaccines are effective in preventing HPV infections thus HPV-related cancers worldwide. Studies on the clinical trials of the 2v Cervarix™ and the 4v Gardasil® have suggested that immunization with either of these vaccines provided some level of protection against other HPV types that are closely related to the types contained in the vaccines. Here we conducted a preliminary evaluation on the ability to induce cross-neutralizing antibodies in rhesus monkeys by a 3v HPV vaccine that targets HPV16, 18, and 58 and it is specifically designed for Chinese women. We found that this vaccine is no less than Gardasil® in terms of the ability to induce NAbs against non-vaccine types of HPV in rhesus macaques. These results provided evidence from the immunogenicity point of view that the KLWS 3v HPV vaccine is a strong competitor to the imported 2v and 4v HPV vaccines currently available on the market.
人乳头瘤病毒（HPV）不仅会引起大多数宫颈癌，还会引起阴道癌、外阴癌、阴茎癌、肛门癌、直肠癌和口咽癌。全世界每年有 20 万名女性死于宫颈癌，而中国约占 10%。HPV 疫苗可有效预防 HPV 感染，从而预防全球 HPV 相关癌症。对 2v Cervarix™ 和 4v Gardasil®临床试验的研究表明，接种这两种疫苗中的任何一种都能提供针对与疫苗中包含的类型密切相关的其他 HPV 类型的一定程度的保护。在这里，我们用针对 HPV16、18 和 58 的 3v HPV 疫苗对恒河猴进行了交叉中和抗体诱导能力的初步评估，该疫苗专门针对中国女性。我们发现，该疫苗在诱导恒河猴对非疫苗型 HPV 的 NAb 方面的能力不亚于 Gardasil®。这些结果从免疫原性角度提供了证据，表明 KLWS 3v HPV 疫苗是目前市场上进口的 2v 和 4v HPV 疫苗的有力竞争者。
